AIMT Aimmune Therapeutics Inc

Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today reported findings from pre-randomization, preliminary clinical data collected from the European screening population of the PALISADE trial in Aimmune’s AR101 program. In addition, the company reported observations from a survey on current management and use of oral immunotherapy for peanut allergy across Western Europe. The data were presented at the 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress in Helsinki.

AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. The Phase 3 PALISADE trial of AR101 enrolled 554 peanut-allergic patients ages 4–49 in eight countries in Europe and in the United States and Canada.

“Food allergy is a growing problem in Europe, with a high unmet medical need due to the potential severity of reactions, the difficulty of avoiding trace amounts of the food and the resulting anxiety that leads to reduced quality of life,” said Sue Barrowcliffe, General Manager of Aimmune Europe. “Consequently we were delighted to have been able to include eight EU countries and more than 100 patients in our Phase 3 PALISADE trial, including many with multiple food allergies. The screening data from these patients that we have presented at EAACI provide an interesting insight into the characteristics of patients who are sensitive to very small amounts of peanut protein. Once the trial is completed, we will also be able to examine in detail the links between baseline characteristics and outcomes, from both an efficacy and a safety perspective.”

Aimmune presented a preliminary dataset of 166 patients in Europe who underwent a screening double-blind, placebo-controlled food challenge (DBPCFC) to determine eligibility for the PALISADE trial (57% ages 4–11, 28% ages 12–17, and 15% ages 18–55; 59% male). The DBPCFC allowed a progression of doses of peanut protein up to a dose of 100 mg (1 mg, 3 mg, 10 mg, 30 mg, and 100 mg). Patients who reacted with dose-limiting symptoms at or before the 100-mg dose (“reactors”) were eligible for randomization into the trial.

Observations from preliminary evaluable baseline characteristics results from these patients included the following:

  • Sixty-two percent of the subjects screened were reactors, who experienced dose-limiting symptoms in the DBPCFC at or before the 100-mg dose (median = 30 mg dose, meaning a cumulative amount of 44 mg peanut protein); 38% were “non-reactors” who consumed all doses in the DBPCFC with no dose-limiting symptoms
  • Reactors had a statistically significant larger peanut skin-prick test (SPT) wheal diameters, a higher peanut-specific IgE (psIgE) and higher Ara h 2–specific IgE than non-reactors. Ara h 2–specific IgE demonstrated greatest sensitivity and specificity for discriminating between reactors and non-reactors, based on receiver operating characteristic (ROC) curve analysis of the data
  • SPT, peanut-specific IgE and Ara h 2 were not associated with the severity of reactions during the screening DBPCFC

“We are looking forward to analyzing the full European and North American dataset from PALISADE to learn more about the relationships between baseline measurements and reactions to peanut, as well as to explore geographic differences in the peanut-allergic populations and their management,” said Daniel Adelman, M.D., Chief Medical Officer of Aimmune. “These data, along with those from the other studies in our AR101 program, provide valuable information that helps determine the most appropriate practical use of AR101 on a large scale. We are particularly interested in seeing the screenings for the Phase 3 ARTEMIS trial for peanut-allergic children and adolescents in Europe, which will include patients who react at or before a 300-mg dose of peanut protein.”

Aimmune also presented the results from a survey of physicians across six Western European countries who offer oral immunotherapy to peanut-allergic patients. Interviews with 39 physicians revealed substantial variability in approaches for peanut oral immunotherapy within and across European countries, showing that there is currently no standardized approach or product for peanut oral immunotherapy in Europe.

The posters associated with the abstracts “Clinical and immunologic characteristics of European patients screened for PALISADE” (#0371, Vereda A, et al.) and “Current Management and Use of Oral Immunotherapy for Peanut Allergy Across Western Europe” (#1369, Radwan A, et al.). are available at www.aimmune.com in the Events section under the News & Events tab.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmune’s expectations for the potential predictive value of biomarkers for AR101; Aimmune’s expectations for its PALISADE and ARTEMIS trials of AR101; Aimmune’s expectations regarding the potential benefits of AR101; and Aimmune’s expectations regarding potential applications of the CODIT™ approach to treating life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the expectation that Aimmune will need additional funds to finance its operations; the company’s ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; the possibility that Aimmune’s clinical trials will not be successful; Aimmune’s dependence on the success of AR101; the company’s reliance on third parties for the manufacture of the company’s product candidates; possible regulatory developments in the United States and foreign countries; and the company’s ability to attract and retain senior management personnel. These and other risks and uncertainties are described more fully in Aimmune's most recent filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

EN
20/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aimmune Therapeutics Inc

 PRESS RELEASE

European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatm...

VEVEY, Switzerland & LONDON--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc., a Nestlé Health Science Company, today announced that the European Commission (EC) has approved PALFORZIA® [defatted powder of Arachis hypogaea L., semen (peanuts)] for the treatment of peanut allergy. PALFORZIA is indicated in patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy in conjunction with a peanut-avoidant diet and may be continued in patients 18 years of age and older. “Today’s approval is a historic moment for the millions of people living with potentially life-threatening peanut allerg...

Wedbush Research
  • Wedbush Research
GRUB GRUBHUB INC
W WAYFAIR INC.
2454 MEDIATEK CORPORATION
LOGI LOGITECH INTERNATIONAL S.A.
VMW VMWARE INC. CLASS A
QRVO QORVO INC.
BLUE BLUEBIRD BIO INC.
XOMA XOMA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
STX SEAGATE TECHNOLOGY PLC
SQ SQUARE INC. CLASS A
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RTRX TRAVERE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
PRTK PARATEK PHARMACEUTICALS INC
PCRX PACIRA BIOSCIENCES INC.
ORCL ORACLE CORPORATION
OMER OMEROS CORPORATION
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MYOK MYOKARDIA INC.
MU MICRON TECHNOLOGY INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
LOW LOWE'S COMPANIES INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
ICPT INTERCEPT PHARMACEUTICALS INC.
HTGC HERCULES CAPITAL INC.
HD HOME DEPOT INC.
GRPN GROUPON INC.
GOOGL ALPHABET INC. CLASS A
GDDY GODADDY INC. CLASS A
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
ETSY ETSY INC.
EPZM EPIZYME INC.
EIGR EIGER BIOPHARMACEUTICALS
EBAY EBAY INC.
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
CATB CATABASIS PHARMACEUTICALS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BBY BEST BUY CO. INC.
ALXN ALEXION PHARMACEUTICALS INC.
AIMT AIMMUNE THERAPEUTICS INC
AGTC APPLIED GENETIC TECHNOLOGIES
ACOR ACORDA THERAPEUTICS INC.
ABUS ARBUTUS BIOPHARMA CORP.
OSTK OVERSTOCK.COM INC.
MRVL MARVELL TECHNOLOGY GROUP LTD.
WD WALKER & DUNLOP INC.
SWKS SKYWORKS SOLUTIONS INC.
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
ALPN ALPINE SELECT AG
BLDR BUILDERS FIRSTSOURCE INC.
GLUU GLU MOBILE INC.
ZNGA ZYNGA INC. CLASS A
HPE HEWLETT PACKARD ENTERPRISE CO.
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
MRUS MERUS B V
ALBO ALBIREO PHARMA
IAC IAC/INTERACTIVECORP
MGEN MIRAGEN THERAPEUTICS
CRVS CORVUS PHARMACEUTICALS
UAA UNDER ARMOUR INC. CLASS A
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
ASND ASCENDANT RESOURCES INC
MRSN MERSANA THERAPEUTICS
SYBX SYNLOGIC
GTHX G1 THERAPEUTICS
ROKU ROKU INC. CLASS A
BHVN BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
VRNA VERONA PHARMA ADS
ANGI ANGI INC. CLASS A
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
HEAR TURTLE BEACH CORP.
SURF SURFACE ONCOLOGY
IDRA IDERA PHARMACEUTICALS
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
APTX APTINYX
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
MGTA MAGENTA THERAPEUTICS
ETTX ENTASIS THERAPEUTICS HOLDINGS
ARAV ARAVIVE
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
AQST AQUESTIVE THERAPEUTICS
RGLS INC.
DELL REGULUS THERAPEUTICS
ORTX DELL TECHNOLOGIES INC.
HARP ORCHARD THERAPEUTICS
TCRR HARPOON THERAPEUTICS
FENC TCR2 THERAPEUTICS
ISEE FENNEC PHARMA
IMUX IVERIC BIO
INTC IMMUNIC INC
SCPL INTEL CORP
BCEL SCIPLAY
CHWY ATRECA
PRVL CHEWY INC. CLASS A
MLND PREVAIL THERAPEUTICS
KRTX MILLENDO THERAPEUTICS
STOK KARUNA THERAPEUTICS INC.
AXLA STOKE THERAPEUTICS
IGMS AXCELLA HEALTH
SWTX IGM BIOSCIENCES
VIE SPRINGWORKS THERAPEUTICS
BEAM VIELA BIO
IDYA BEAM THERAPEUTICS
GBIO IDEAYA BIOSCIENCES
FUSN GENERATION BIO
ITOS FUSION PHARMACEUTICALS INC
INZY ITEOS THERAPEUTICS
FRLN INOZYME PHARMA
UMRX FREELINE THERAPEUTICS
SHOP COGENT BIOSCIENCES
CRSR SHOPIFY
CORSAIR GAMING
Wedbush Research
  • Wedbush Research
2454 MEDIATEK CORPORATION
UBI UBISOFT ENTERTAINMENT SA
VMW VMWARE INC. CLASS A
QRVO QORVO INC.
USB U.S. BANCORP
BLUE BLUEBIRD BIO INC.
XOMA XOMA
XENE XENON PHARMACEUTICALS INC
WWW WOLVERINE WORLD WIDE INC.
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
VLY VALLEY NATIONAL BANCORP
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
STX SEAGATE TECHNOLOGY PLC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RTRX TRAVERE THERAPEUTICS INC.
RF REGIONS FINANCIAL CORPORATION
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
PRTK PARATEK PHARMACEUTICALS INC
PCRX PACIRA BIOSCIENCES INC.
OMER OMEROS CORPORATION
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MYOK MYOKARDIA INC.
MU MICRON TECHNOLOGY INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
KEY KEYCORP
IMAX IMAX CORPORATION
ICPT INTERCEPT PHARMACEUTICALS INC.
HBAN HUNTINGTON BANCSHARES INCORPORATED
GPC GENUINE PARTS COMPANY
GOOGL ALPHABET INC. CLASS A
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EWBC EAST WEST BANCORP INC.
EPZM EPIZYME INC.
EIGR EIGER BIOPHARMACEUTICALS
CVBF CVB FINANCIAL CORP.
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
CATB CATABASIS PHARMACEUTICALS
BPMC BLUEPRINT MEDICINES CORP.
BPFH BOSTON PRIVATE FINANCIAL HOLDINGS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AZO AUTOZONE INC.
ATVI ACTIVISION BLIZZARD INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
ALXN ALEXION PHARMACEUTICALS INC.
AIMT AIMMUNE THERAPEUTICS INC
AGTC APPLIED GENETIC TECHNOLOGIES
ABUS ARBUTUS BIOPHARMA CORP.
AAP ADVANCE AUTO PARTS INC.
MRVL MARVELL TECHNOLOGY GROUP LTD.
SWKS SKYWORKS SOLUTIONS INC.
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
ALPN ALPINE SELECT AG
BBBY BED BATH & BEYOND INC.
EA ELECTRONIC ARTS INC.
HPE HEWLETT PACKARD ENTERPRISE CO.
TWTR TWITTER INC.
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
MRUS MERUS B V
ALBO ALBIREO PHARMA
MGEN MIRAGEN THERAPEUTICS
CRVS CORVUS PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
ASND ASCENDANT RESOURCES INC
MRSN MERSANA THERAPEUTICS
SYBX SYNLOGIC
GTHX G1 THERAPEUTICS
BHVN BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
VRNA VERONA PHARMA ADS
ORLY O'REILLY AUTOMOTIVE
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
HEAR TURTLE BEACH CORP.
SURF SURFACE ONCOLOGY
IDRA IDERA PHARMACEUTICALS
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
MGTA MAGENTA THERAPEUTICS
ARAV ARAVIVE
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
AQST AQUESTIVE THERAPEUTICS
RGLS INC.
DELL REGULUS THERAPEUTICS
ORTX DELL TECHNOLOGIES INC.
HARP ORCHARD THERAPEUTICS
TCRR HARPOON THERAPEUTICS
FENC TCR2 THERAPEUTICS
ISEE FENNEC PHARMA
IMUX IVERIC BIO
INTC IMMUNIC INC
BCEL INTEL CORP
PRVL ATRECA
MLND PREVAIL THERAPEUTICS
KRTX MILLENDO THERAPEUTICS
STOK KARUNA THERAPEUTICS INC.
AXLA STOKE THERAPEUTICS
IGMS AXCELLA HEALTH
SWTX IGM BIOSCIENCES
VIE SPRINGWORKS THERAPEUTICS
BEAM VIELA BIO
IDYA BEAM THERAPEUTICS
GBIO IDEAYA BIOSCIENCES
ITOS GENERATION BIO
INZY ITEOS THERAPEUTICS
FRLN INOZYME PHARMA
UMRX FREELINE THERAPEUTICS
COGENT BIOSCIENCES
Andreas Argyrides ... (+9)
  • Andreas Argyrides
  • Ashiq Mubarack
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe
BLUE BLUEBIRD BIO INC.
XOMA XOMA
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RTRX TRAVERE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRTK PARATEK PHARMACEUTICALS INC
PCRX PACIRA BIOSCIENCES INC.
OMER OMEROS CORPORATION
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
MYOK MYOKARDIA INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
ICPT INTERCEPT PHARMACEUTICALS INC.
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FATE FATE THERAPEUTICS INC
EPZM EPIZYME INC.
EIGR EIGER BIOPHARMACEUTICALS
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
CATB CATABASIS PHARMACEUTICALS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ALXN ALEXION PHARMACEUTICALS INC.
AIMT AIMMUNE THERAPEUTICS INC
AGTC APPLIED GENETIC TECHNOLOGIES
ABUS ARBUTUS BIOPHARMA CORP.
ALPN ALPINE SELECT AG
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
MRUS MERUS B V
ALBO ALBIREO PHARMA
MGEN MIRAGEN THERAPEUTICS
CRVS CORVUS PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
ASND ASCENDANT RESOURCES INC
MRSN MERSANA THERAPEUTICS
SYBX SYNLOGIC
GTHX G1 THERAPEUTICS
BHVN BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
VRNA VERONA PHARMA ADS
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
IDRA IDERA PHARMACEUTICALS
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
MGTA MAGENTA THERAPEUTICS
ARAV ARAVIVE
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
AQST AQUESTIVE THERAPEUTICS
RGLS INC.
ORTX REGULUS THERAPEUTICS
HARP ORCHARD THERAPEUTICS
TCRR HARPOON THERAPEUTICS
FENC TCR2 THERAPEUTICS
ISEE FENNEC PHARMA
IMUX IVERIC BIO
BCEL IMMUNIC INC
PRVL ATRECA
MLND PREVAIL THERAPEUTICS
KRTX MILLENDO THERAPEUTICS
STOK KARUNA THERAPEUTICS INC.
AXLA STOKE THERAPEUTICS
IGMS AXCELLA HEALTH
SWTX IGM BIOSCIENCES
VIE SPRINGWORKS THERAPEUTICS
BEAM VIELA BIO
IDYA BEAM THERAPEUTICS
GBIO IDEAYA BIOSCIENCES
ITOS GENERATION BIO
INZY ITEOS THERAPEUTICS
FRLN INOZYME PHARMA
UMRX FREELINE THERAPEUTICS
COGENT BIOSCIENCES
Andreas Argyrides ... (+3)
  • Andreas Argyrides
  • Liana Moussatos
  • Shveta Dighe

ResearchPool Subscriptions

Get the most out of your insights

Get in touch